Serum interleukin-6 is a predictive biomarker for ketamine's antidepressant effect in treatment-resistant patients with major depression

Biological Psychiatry

Volumn 77, Issue 3, 2015, Pages e19-e20

  Yang, Jian Jun ^a   Wang, Nan ^a   Yang, Chun ^c   Shi, Jin Yun ^a,b   Yu, Hai Ying ^b   Hashimoto, Kenji ^c  

^a NANJING UNIVERSITY   (China)

^b Mental Health Center of Military   (China)

^c CHIBA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1BETA; INTERLEUKIN 6; KETAMINE; TUMOR NECROSIS FACTOR ALPHA; ANTIDEPRESSANT AGENT; IL1B PROTEIN, HUMAN; IL6 PROTEIN, HUMAN; KYNURENINE; PHARMACOLOGICAL BIOMARKER; TRYPTOPHAN;

ANTIDEPRESSANT ACTIVITY; CHRONOTHERAPY; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; HAMILTON DEPRESSION RATING SCALE; HUMAN; LETTER; MAJOR DEPRESSION; MEDIATOR RELEASE; MENTAL PATIENT; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSYCHOPHARMACOTHERAPY; TREATMENT OUTCOME; TREATMENT RESISTANT DEPRESSION; TREATMENT RESPONSE; BLOOD; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; HOSPITAL PATIENT; PSYCHOLOGICAL RATING SCALE;

ANTIDEPRESSIVE AGENTS; BIOMARKERS, PHARMACOLOGICAL; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; HUMANS; INPATIENTS; INTERLEUKIN-1BETA; INTERLEUKIN-6; KETAMINE; KYNURENINE; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME; TRYPTOPHAN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84927641011     PISSN: 00063223     EISSN: 18732402     Source Type: Journal    
DOI: 10.1016/j.biopsych.2014.06.021     Document Type: Letter

References (10)

1. Aan Het Rot M, Zarate CA Jr, Charney DS, Mathew SJ (2012): Ketamine for depression: Where do we go from here? Biol Psychiatry 72:537-547.
2. Krystal JH, Sanacora G, Duman RS (2013): Rapid-acting glutamatergic antidepressants: The path to ketamine and beyond. Biol Psychiatry 73:1133-1141.
3. Zarate CA Jr, Brutsche NE, Laje G, Luckenbaugh DA, Venkata SLV, Ramamoorthy A, et al. (2012): Relationship of ketamine s plasma metabolites with response, diagnosis, and side effects in major depression. Biol Psychiatry 72:331-338.
4. Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Green CE, Perez AM, et al. (2013): Antidepressant efficacy of ketamine in treatment-resistant major depression: A two-site randomized controlled trial. Am J Psychiatry 170:1134-1142.
5. Zarate CA Jr, Mathews DC, Furey ML (2013): Human biomarkers of rapid antidepressant effects. Biol Psychiatry 73:1142-1155.
6. Erhardt S, Lim CK, Linderholm KR, Janelidze S, Lindqvist D, Samuelsson M, et al. (2013): Connecting inflammation with glutamate agonism in suicidality. Neuropsychopharmacology 38:743-752.
7. Miller AH, Maletic V, Raison CL (2009): Inflammation and its discontents: The role of cytokines in the pathophysiology of major depression. Biol Psychiatry 65:732-741.
8. Serafini G, Pompili M, Elena Seretti M, Stefani H, Palermo M, Coryell W, Girardi P (2013): The role of inflammatory cytokines in suicidal behavior: A systematic review. Eur Neuropsychopharmacol 23:1672-1686.
9. Maes M, Anderson G, Kubera M, Berk M (2014): Targeting classical IL-6 signalling or IL-6 trans-signalling in depression? Expert Opin Ther Targets 18:495-512.
10. Zunszain PA, Horowitz MA, Cattaneo A, Lupi MM, Pariante CM (2013): Ketamine: Synaptogenesis, immunomodulation and glycogen synthase kinase-3 as underlying mechanisms of its antidepressant properties. Mol Psychiatry 18:1236-1241.